


CLAIMS

What is claimed is:

1. A compound of Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof, wherein

D is N or CH;

R<sup>1</sup> is aryl or heteroaryl, where said aryl or said heteroaryl may be optionally substituted one or more times with C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, C<sub>1</sub>-C<sub>6</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>6</sub> alkylsulfonyl, oxo, hydroxy, mercapto, carboxy, tetrazolyl, carbamoyl optionally substituted with alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, halogen, C<sub>1</sub>-C<sub>6</sub> haloalkyl, heterocyclyl, heteroaryl, aryl, cyano, azido, nitro, or -NR<sup>4</sup>R<sup>5</sup>;

a is 1 or 2;

y is 0, 1, or 2;

R<sup>2</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, halogen, heterocyclyl, aryl, heteroaryl, cyano, azido, nitro, -OR<sup>8</sup>, -OR<sup>6</sup>R<sup>8</sup>, -R<sup>8</sup>R<sup>7</sup>, -R<sup>6</sup>R<sup>7</sup>, S(O)<sub>y</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)OR<sup>7</sup>, -C(O)NR<sup>4</sup>R<sup>5</sup>, -NR<sup>7</sup>(C=NR<sup>4</sup>)NR<sup>4</sup>R<sup>5</sup>, -OC(O)NR<sup>4</sup>R<sup>5</sup>, -OC(O)OR<sup>7</sup>, -C(=NR<sup>4</sup>)NR<sup>4</sup>R<sup>5</sup>, -NR<sup>4</sup>R<sup>5</sup>, -OC(O)R<sup>7</sup>, or -NR<sup>7</sup>C(O)R<sup>7</sup>;

R<sup>3</sup> is -(Q)<sub>p</sub>-(Q<sup>1</sup>)

where

Q is O, N(R<sup>8</sup>) or S(O)<sub>y</sub>,

p is 0 or 1,

y is 0, 1, or 2, and

Q<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, aryl, aryl substituted with -C(O)N(H)R<sup>6</sup>NR<sup>4</sup>R<sup>5</sup> or -OC(H)(OH)R<sup>6</sup>NR<sup>4</sup>R<sup>5</sup>, heteroaryl, aralkyl, or -R<sup>6</sup>NR<sup>4</sup>R<sup>5</sup>;

R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are bound form a heterocyclyl;

R<sup>6</sup> is alkylene, arylene, heteroarylene, cycloalkylene, alkenylene, cycloalkenylene, or alkynylene;

R<sup>7</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, -NR<sup>4</sup>R<sup>5</sup>, aryl, aralkyl, heteroaryl, cycloalkyl, heterocyclyl, -S(O)<sub>y</sub>R<sup>8</sup>, -C(O)R<sup>8</sup>, -C(O)OR<sup>8</sup>, -C(O)NR<sup>4</sup>R<sup>5</sup>, -S(O)<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, -NR<sup>7</sup>(C=NR<sup>4</sup>)NR<sup>4</sup>R<sup>5</sup>, -OC(O)NR<sup>4</sup>R<sup>5</sup>, -OC(O)OR<sup>8</sup>, -C(=NR<sup>4</sup>)NR<sup>4</sup>R<sup>5</sup>, -NR<sup>4</sup>R<sup>5</sup>, or -NR<sup>7</sup>C(O)R<sup>7</sup>

R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, -NR<sup>4</sup>R<sup>5</sup>, aryl, aralkyl, heteroaryl, cycloalkyl, heterocyclyl, or -S(O)<sub>2</sub>R<sup>9</sup>;


R<sup>9</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl;

R' is C<sub>1</sub>-C<sub>3</sub> alkylene; and

R'' is -OR<sup>7</sup>, -OC(O)NR<sup>4</sup>R<sup>5</sup>, -OC(O)OR<sup>7</sup>, -OC(O)R<sup>7</sup>.

2. The compound of claim 1 wherein R<sup>1</sup> is optionally substituted aryl.
3. The compound of claim 2 wherein R<sup>1</sup> is optionally substituted phenyl.
4. The compound of claim 3 wherein R<sup>1</sup> is phenyl is substituted in the para position.
5. The compound of claim 1 wherein R<sup>3</sup> is further defined wherein Q is N(R<sup>8</sup>), where R<sup>8</sup> is H, p is 1, and Q<sup>1</sup> is optionally substituted aryl.
6. The compound of claim 5 wherein Q<sup>1</sup> is optionally substituted phenyl.
7. The compound of claim 6 wherein the phenyl is substituted in the meta or para position.

8. A method for the treatment or prophylaxis of a disorder in a mammal, said disorder being characterized by misregulation of GSK-3, comprising administering a compound of Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof, wherein

D is N or CH;

R¹ is hydrogen, C₁-C₆ alkyl, C₁-C₄ alkenyl, C₁-C₄ alkynyl, C₁-C₃ alkoxy, halogen, hydroxy, cyano, -S(O)<sub>y</sub>C₁-C₃ alkyl, -NR⁴R⁵, aryl, or heteroaryl, where said aryl or said heteroaryl may be optionally substituted one or more times with C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ alkylsulfonyl, oxo, hydroxy, mercapto, carboxy, tetrazolyl, carbamoyl optionally substituted with alkyl, aminosulfonyl optionally substituted by alkyl, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, halogen, C₁-C₆ haloalkyl, heterocyclyl, heteroaryl, aryl, cyano, azido, nitro, or -NR⁴R⁵;

a is 1 or 2;

y is 0, 1, or 2;

R² is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkenyl, C₁-C₆ alkynyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, halogen, heterocyclyl, aryl, heteroaryl, cyano, azido, nitro, -OR⁸, -OR⁶R⁸, -R⁶R⁷, -R⁶R⁷, S(O)<sub>y</sub>R⁷, -C(O)R⁷, -C(O)OR⁷, -C(O)NR⁴R⁵, -NR⁷(C=NR⁴)NR⁴R⁵, -OC(O)NR⁴R⁵, -OC(O)OR⁷, -C(=NR⁴)NR⁴R⁵, -NR⁴R⁵, -OC(O)R⁷, -NR⁷C(O)R⁷;

R³ is -(Q)<sub>p</sub>-(Q¹)

where

Q is O, N(R⁸) or S(O)<sub>y</sub>, p is 0 or 1, y is 0, 1, or 2 and

Q<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, aryl, aryl substituted with -C(O)N(H)R<sup>6</sup>NR<sup>4</sup>R<sup>5</sup> or -OC(H)(OH)R<sup>6</sup>NR<sup>4</sup>R<sup>5</sup>, heteroaryl, aralkyl, or -R<sup>6</sup>NR<sup>4</sup>R<sup>5</sup>;

R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or R<sup>4</sup> and R<sup>5</sup>, together with the nitrogen atom to which they are bound, form a heterocyclyl;

R<sup>6</sup> is alkylene, arylene, heteroarylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene;

R<sup>7</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, -NR<sup>4</sup>R<sup>5</sup>, aryl, aralkyl, heteroaryl, cycloalkyl, heterocyclyl, -S(O)<sub>y</sub>R<sup>8</sup>, -C(O)R<sup>8</sup>, -C(O)OR<sup>8</sup>, -C(O)NR<sup>4</sup>R<sup>5</sup>, -S(O)<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, -NR'(C=NR<sup>4</sup>)NR<sup>4</sup>R<sup>5</sup>, -OC(O)NR<sup>4</sup>R<sup>5</sup>, -OC(O)OR<sup>8</sup>, -C(=NR<sup>4</sup>)NR<sup>4</sup>R<sup>5</sup>, -NR<sup>4</sup>R<sup>5</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>

R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, -NR<sup>4</sup>R<sup>5</sup>, aryl, aralkyl, heteroaryl, cycloalkyl, heterocyclyl, or -S(O)<sub>2</sub>R<sup>9</sup>;

R<sup>9</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl;

R' is C<sub>1</sub>-C<sub>3</sub> alkylene; and

R'' is -OR<sup>7</sup>, -OC(O)NR<sup>4</sup>R<sup>5</sup>, -OC(O)OR<sup>7</sup>, -OC(O)R<sup>7</sup>.

9. The compound of claim 8 wherein R<sup>1</sup> is optionally substituted aryl.
10. The compound of claim 9 wherein R<sup>1</sup> is optionally substituted phenyl.
11. The compound of claim 10 wherein R<sup>1</sup> is phenyl is substituted in the para position.
12. The compound of claim 8 wherein R<sup>3</sup> is further defined wherein Q is N(R<sup>8</sup>), where R<sup>8</sup> is H, p is 1, and Q<sup>1</sup> is optionally substituted aryl.
13. The compound of claim 12 wherein Q<sup>1</sup> is optionally substituted phenyl.
14. The compound of claim 13 wherein the phenyl is substituted in the meta or para position.
15. A method as claimed in claim 14, wherein the compound is selected from the group consisting of:

N-Cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-Cyclopropyl-N-methyl-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
4-Pyrazolo[1,5-b]pyridazin-3-yl-N-(2,2,2-trifluoroethyl)-2-pyrimidinamine;  
N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-(4-Chlorophenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-(4-Fluorophenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
3-[(4-Pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)amino]benzonitrile;  
4-[(4-Pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)amino]benzoic acid;  
4-Pyrazolo[1,5-b]pyridazin-3-yl-N-[3-(trifluoromethyl)phenyl]-2-pyrimidinamine;  
N-(3-Nitrophenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-(2-Chlorophenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-(4-Methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
4-Pyrazolo[1,5-b]pyridazin-3-yl-N-(3,4,5-trimethoxyphenyl)-2-pyrimidinamine;  
N-[3-(1,3-Oxazol-5-yl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-(4-Pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)-1H-benzimidazol-6-amine;  
N-(4-Pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)-1,3-benzoxazol-2-amine;  
N-(6-Chloro-1H-benzimidazol-2-yl)-N-(4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)amine;  
N-(4-Chlorobenzyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N<sup>1</sup>,N<sup>1</sup>-Dimethyl-N<sup>3</sup>-(4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)-1,3-propanediamine;  
N-[3-(4-Morpholinyl)propyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-[3-(4-Methyl-1-piperazinyl)propyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
1-[3-[(4-Pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)amino]propyl]-2-pyrrolidinone;  
N-[3-Chloro-4-(4-methyl-1-piperazinyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-[4-(4-Methyl-1-piperazinyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-[3-Methyl-4-(4-methyl-1-piperazinyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-[4-(4-Methyl-1-piperazinyl)-3-(trifluoromethyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-[3-Chloro-4-(4-morpholinyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-[4-[(Diethylamino)methyl]phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-[2-(Diethylamino)ethyl]-4-[(4-pyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinyl]amino]benzamide;  
N-Cyclopropyl-4-(2-methylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
N-Cyclopropyl-4-(2-ethylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
4-(2-Butylpyrazolo[1,5-b]pyridazin-3-yl)-N-cyclopropyl-2-pyrimidinamine;  
N-[4-(4-Methyl-1-piperazinyl)phenyl]-4-(2-methylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
4-(2-Ethylpyrazolo[1,5-b]pyridazin-3-yl)-N-[4-(4-methyl-1-piperazinyl)phenyl]-2-pyrimidinamine;  
4-(2-Butylpyrazolo[1,5-b]pyridazin-3-yl)-N-[4-(4-methyl-1-piperazinyl)phenyl]-2-pyrimidinamine;  
N-Cyclopropyl-4-(6-methoxypyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
4-(6-Methoxypyrazolo[1,5-b]pyridazin-3-yl)-N-[4-(4-methyl-1-piperazinyl)phenyl]-2-pyrimidinamine;  
3-[2-(Cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-b]pyridazin-6-ol;  
N-Cyclopropyl-4-(6-isopropoxypyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
N-[4-(6-Isopropoxypyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]amine;  
3-[2-(Cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-b]pyridazin-6-yl trifluoromethanesulfonate;  
4-[6-(2-Chlorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-cyclopropyl-2-pyrimidinamine;  
N-Cyclopropyl-4-[6-(2-thienyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
N-Cyclopropyl-4-[6-(4-fluorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
N-Cyclopropyl-4-(6-vinylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
N-Cyclopropyl-4-[6-(4-morpholinyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
N-Cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-b]pyridazin-6-amine;  
N-Cyclopropyl-4-[6-(1-pyrrolidinyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
N-Cyclopropyl-4-[6-(2-fluoro-4-pyridinyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
N-Cyclopropyl-4-[6-(phenylsulfanyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
4-[6-(4-Fluorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-(4-methoxyphenyl)-2-pyrimidinamine;  
4-[6-(4-Fluorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]-2-pyrimidinamine;

N<sup>1</sup>,N<sup>1</sup>-Dimethyl-N<sup>4</sup>-{4-[6-(4-morpholinyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinyl}-1,4-benzenediamine;  
1-(Dimethylamino)-3-[4-({4-[6-(4-morpholinyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinyl}amino)phenoxy]-2-propanol;  
N-(1,3-benzodioxol-5-yl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-[3-Methoxy-5-(trifluoromethyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
4-[(4-Pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)amino]benzonitrile;  
N-(4-Nitrophenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-(3-Methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
N-(3,5-Dimethylphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;  
4-[2-(4-methoxyphenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-phenylpyrimidin-2-amine;  
4-[2-(4-methoxyphenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-[3-(trifluoromethyl)phenyl]pyrimidin-2-amine;  
N-(3,4-difluorophenyl)-4-[2-(4-methoxyphenyl)pyrazolo[1,5-b]pyridazin-3-yl]pyrimidin-2-amine;  
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-(4-methoxyphenyl)pyrazolo[1,5-b]pyridazin-3-yl]pyrimidin-2-amine;  
N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[2-(4-methoxyphenyl)pyrazolo[1,5-b]pyridazin-3-yl]pyrimidin-2-amine;  
N-phenyl-4-[2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl]pyrimidin-2-amine;  
N-[3-(trifluoromethyl)phenyl]-4-[2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl]pyrimidin-2-amine;  
N-(3,4-difluorophenyl)-4-[2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl]pyrimidin-2-amine;  
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl]pyrimidin-2-amine;  
N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl]pyrimidin-2-amine;  
4-[2-(4-chlorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-phenylpyrimidin-2-amine;  
4-[2-(4-chlorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-[3-(trifluoromethyl)phenyl]pyrimidin-2-amine;

4-[2-(4-chlorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-(3,4-difluorophenyl)pyrimidin-2-amine;

4-[2-(4-chlorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrimidin-2-amine;

4-[2-(4-chlorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-[4-chloro-3-(trifluoromethyl)phenyl]pyrimidin-2-amine;

4-[6-methyl-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl]-N-phenylpyrimidin-2-amine;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[6-methyl-2-(4-methylphenyl)pyrazolo[1,5-b]pyridazin-3-yl]pyrimidin-2-amine;

N-[3,5-bis(trifluoromethyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-(3,5-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-(4-sec-butylphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-(4-tert-butylphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-(3,5-dichlorophenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-(3,4-dichlorophenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-(3,5-difluorophenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-[3-bromo-5-(trifluoromethyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

3-[(4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)amino]-5-(trifluoromethyl)benzamide;

N-(3,4-difluorophenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-[4-chloro-3-(trifluoromethyl)phenyl]-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine;

N-phenyl-4-(2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;

4-(2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-N-[3-(trifluoromethyl)phenyl]-2-pyrimidinamine;

N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;

N-(3,5-difluorophenyl)-4-(2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;

N-(3,4-difluorophenyl)-4-(2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;

4-[2-(4-fluorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-phenyl-2-pyrimidinamine;



N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-(4-fluorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
4-[2-(4-fluorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-[3-(trifluoromethyl)phenyl]-2-pyrimidinamine;  
N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[2-(4-fluorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
N-(3,4-difluorophenyl)-4-[2-(4-fluorophenyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
N-phenyl-4-{2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl}-2-pyrimidinamine;  
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-{2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl}-2-pyrimidinamine;  
N-[3-(trifluoromethyl)phenyl]-4-{2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl}-2-pyrimidinamine;  
N-[4-chloro-3-(trifluoromethyl)phenyl]-4-{2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl}-2-pyrimidinamine;  
N-(3,4-difluorophenyl)-4-{2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl}-2-pyrimidinamine;  
4-(6-methyl-2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-N-phenyl-2-pyrimidinamine;  
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(6-methyl-2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
4-(6-methyl-2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-N-[3-(trifluoromethyl)phenyl]-2-pyrimidinamine;  
N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(6-methyl-2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
N-(3,4-difluorophenyl)-4-(6-methyl-2-phenylpyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
4-(6-methyl-2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl)-N-phenyl-2-pyrimidinamine;  
4-(6-methyl-2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl)-N-[3-(trifluoromethyl)phenyl]-2-pyrimidinamine;  
N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(6-methyl-2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;  
N-(3,4-difluorophenyl)-4-(6-methyl-2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinamine;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-{6-methyl-2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-b]pyridazin-3-yl}-2-pyrimidinamine;  
4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-b]pyridazin-3-yl]-N-phenyl-2-pyrimidinamine;  
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-b]pyridazin-3-yl]-N-[3-(trifluoromethyl)phenyl]-2-pyrimidinamine;  
N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
N-(3,4-difluorophenyl)-4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine;  
4-(2-cyclopropylpyrazolo[1,5-b]pyridazin-3-yl)-N-phenylpyrimidin-2-amine;  
4-(2-cyclopropylpyrazolo[1,5-b]pyridazin-3-yl)-N-(3,4-difluorophenyl)pyrimidin-2-amine;  
4-(2-cyclohexylpyrazolo[1,5-b]pyridazin-3-yl)-N-phenylpyrimidin-2-amine;  
4-(2-cyclohexylpyrazolo[1,5-b]pyridazin-3-yl)-N-(3,4-difluorophenyl)pyrimidin-2-amine; or  
a salt, solvate, or physiologically functional derivative thereof.

16. A pharmaceutical composition, comprising:  
a therapeutically effective amount of a compound as claimed in any one of claims 1 to 7, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

17. The pharmaceutical composition of claim 16, further comprising:  
at least one additional agent for the treatment or prophylaxis of diabetes.

18. A pharmaceutical composition, comprising:  
a therapeutically effective amount of a compound as in claims 1 to 15, or a salt, solvate, or a physiologically functional derivative thereof, and one or more of pharmaceutically acceptable carriers, diluents and excipients for preventing or treating conditions mediated by GSK-3.

19. A method of treating a disorder in a mammal, said disorder being mediated by inappropriate GSK-3 activity, comprising:  
administering to said mammal a therapeutically effective amount of a compound as in any one of claims 1 to 15, or a salt, solvate, or a physiologically functional derivative thereof.
20. The method of claim 19, wherein the disorder is Type II Diabetes.
21. A compound as claimed in any of claims 1 to 7, or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.
22. Use of a compound as in any of claims 1 to 15, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate GSK-3 activity.
23. The use of claim 22, wherein the disorder is Type II Diabetes.
24. A method of treating diabetes in a mammal, including administering to said mammal a therapeutically effective amount of a compound as claimed in any of claims 1 to 7, or salt, solvate or physiologically functional derivative thereof.
25. A method of treating diabetes in a mammal, including administering to said mammal therapeutically effective amounts of (i) a compound as in any of claims 1 to 15, or salt, solvate or physiologically functional derivative thereof and (ii) at least one additional anti-diabetic therapy.